Vanda Pharmaceuticals Competitors
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside | Analysts | Market Cap |
|---|---|---|---|---|---|---|---|---|---|
| LLY | Eli Lilly and | Outperform |
16
|
$807.43 | Buy/Sell | $636.99 | 8.68% | 9 | $727.93B |
| JNJ | Johnson & Johnson | Outperform |
9
|
$146.97 | Buy/Sell | $174.55 | 15.67% | 3 | $360.28B |
| MRK | Merck | Outperform |
2
|
$129.49 | Buy/Sell | $130.51 | 11.21% | 11 | $332.03B |
| ABBV | AbbVie | Outperform |
9
|
$157.06 | Buy/Sell | $178.42 | 16.20% | 11 | $279.47B |
| SAN | Sanofi | Outperform |
16
|
89.52€ | Buy/Sell | 102.80€ | 21.76% | 9 | 112.71€B |
| KLAC | KLA Corp | Outperform |
8
|
$779.06 | Buy/Sell | $644.74 | -2.45% | 11 | $103.01B |
| 4502 | Takeda Pharmaceutical Company | Outperform |
5
|
¥4.13k | Buy/Sell | ¥4.74k | 8.85% | 0 | ¥6.49T |
| TEVA | Teva Pharmaceutical Industries | Outperform |
12
|
$16.60 | Buy/Sell | $11.59 | 2.41% | 9 | $18.98B |
| VTRS | Viatris Inc | Hold |
8
|
$10.41 | Buy/Sell | $11.73 | 15.27% | 5 | $13.32B |
| ITCI | Intra-Cellular Therapies | Outperform |
10
|
$65.54 | Buy/Sell | $79.10 | 38.08% | 10 | $6.86B |
| ALKS | Alkermes | Outperform |
10
|
$24.02 | Buy/Sell | $33.27 | 33.22% | 3 | $4.11B |
| INDV | Indivior PLC | Buy |
14
|
£13.57 | Buy/Sell | £28.89 | 127.93% | 4 | £1.95B |